<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848506</url>
  </required_header>
  <id_info>
    <org_study_id>CY 6022</org_study_id>
    <secondary_id>2020-003571-17</secondary_id>
    <nct_id>NCT04848506</nct_id>
  </id_info>
  <brief_title>CY 6022 is an Open Label Study to Collect Long-term Safety and Tolerability Data for CK-3773274</brief_title>
  <official_title>An Open-Label Study of CK-3773274 for Patients With Symptomatic Hypertrophic Cardiomyopathy (HCM) and Left Ventricular Outflow Tract Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytokinetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytokinetics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect long-term safety and tolerability data for CK-3773274&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events observed during dosing of CK-3773274 in patients with oHCM</measure>
    <time_frame>To End of study, up to 5 years</time_frame>
    <description>Patient incidence of reported Adverse Events (AEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events observed during dosing of CK-3773274 in patients with oHCM</measure>
    <time_frame>To End of study, up to 5 years</time_frame>
    <description>Patient incidence of reported Serious Adverse Events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of left ventricular ejection fraction (LVEF) &lt; 50% observed during dosing of CK-3773274 in patients with oHCM</measure>
    <time_frame>To End of study, up to 5 years</time_frame>
    <description>Patient incidence of reported LVEF &lt;50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term effects of CK-3773274 on left ventricular outflow tract gradient (LVOT G)</measure>
    <time_frame>Baseline through the end of participation at 12-week intervals</time_frame>
    <description>Peak LVOT-G at rest</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Obstructive Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>CK-3773274 up to 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm take daily dose of CK-3773274. Each patient will start at the lowest prespecified dose and titrate up to their maximum tolerated dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CK-3773274 (5 - 15 mg)</intervention_name>
    <description>CK-3773274 tablets administered orally</description>
    <arm_group_label>CK-3773274 up to 15 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Completion of a Cytokinetics trial investigating CK-3773274&#xD;
&#xD;
          -  LVEF â‰¥55% at the Screening Visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has taken any investigational study drug other than CK-3773274 within 30 days prior to&#xD;
             screening&#xD;
&#xD;
          -  Since completion of a previous trial of CK-3773274 has:&#xD;
&#xD;
               -  Developed new-onset paroxysmal or permanent atrial fibrillation requiring rhythm&#xD;
                  restoring treatment (eg, direct-current cardioversion, ablation procedure, or&#xD;
                  antiarrhythmic therapy) &lt;30 days prior to screening. Patient may re-screen for CY&#xD;
                  6022 after 30 days if heart rate (HR) &lt;100 bpm and/or rhythm is stable &gt;30 days&#xD;
&#xD;
               -  Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol&#xD;
                  ablation)&#xD;
&#xD;
          -  Has current obstructive coronary artery disease (&gt;70% stenosis documented in one or&#xD;
             more arteries)&#xD;
&#xD;
          -  Has moderate or severe aortic valve stenosis&#xD;
&#xD;
          -  Had a confirmed LVEF &lt;40% with an associated dose interruption during CY 6021&#xD;
&#xD;
          -  Has been treated with drugs that have negative inotropic activity (except for beta-&#xD;
             blockers, calcium channel blockers, or disopyramide) as monotherapy or in combination&#xD;
             within 30 days prior to screening. Patients receiving treatment with disopyramide&#xD;
             require approval from the medical monitor prior to enrollment.&#xD;
&#xD;
          -  History of syncope or sustained ventricular tachyarrhythmia with exercise within 30&#xD;
             days prior to screening&#xD;
&#xD;
          -  History of appropriate ICD shock within 30 days prior to screening&#xD;
&#xD;
          -  Has received treatment with mavacamten within 3 months prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cytokinetics, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cytokinetics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cytokinetics, MD</last_name>
    <phone>650-624-2929</phone>
    <email>medicalaffairs@cytokinetics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine - University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trina Lowther, MD</last_name>
      <phone>503-494-3253</phone>
      <email>lowthert@ohsu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obstructive Hypertrophic Cardiomyopathy</keyword>
  <keyword>oHCM</keyword>
  <keyword>CK-3773274</keyword>
  <keyword>CK-274</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

